Targeted delivery is an important area of biomedical research, which can reduce side effects in clinical field. Various carriers, such as organic, inorganic particles, liposome, polymer, etc., have been utilized in targeted delivery. However, these vehicles have several difficulties such as the comp...
Targeted delivery is an important area of biomedical research, which can reduce side effects in clinical field. Various carriers, such as organic, inorganic particles, liposome, polymer, etc., have been utilized in targeted delivery. However, these vehicles have several difficulties such as the complexity of synthesis, heterogeneous size and shape and lower biocompatibility. Protein nanoparticles could be an attractive candidate as delivery vehicles. Protein nanoparticles have well-defined structure with high symmetry, uniform size and shape. These particles have also biodegradability, greater stability during in vivo circulation and being easy to prepare the particles. And protein nanoparticles can attach drugs, fluorescent dye, enzymes, radioactive isotopes, antigens, or antibodies at desired site depending on their purpose.
In this study, we used Aquifex aeolicus Lumazine synthase (AaLS) as a targeted delivery vehicle. Antibody binding domain (ABD), which was known to selectively bind to Fc part of the antibody, was genetically encoded to AaLS (ABD-AaLS). We have designed a modular delivery platform that can deliver drugs to a variety of cancer cells by binding various antibodies to ABD. This platform can deliver drug to variety of target cancer cells in in vitro.
Recently we have developed a targeted delivery platform using P22 virus-like particle (P22 VLP) that is relatively large-sized protein cage nanoparticles. We covalently attached affibody to exterior surface of P22 VLP using bacterial superglue system. These platforms successfully delivered anticancer drug, doxorubicin, to tumor site and showed tumor specific killing effect.
In addition, we developed the cloaking drug delivery system using mesoporous silica nanoparticles (MSNs). We constructed GST fused affibody molecules and bound these fusion proteins on MSNs as capping materials. This pre-coated nanoparticles blocked nonspecific binding of serum proteins, avoiding immune response, while maintaining targeting ability in vivo.
Our studies demonstrated that protein nanoparticles are promising platforms for diagnostic and/or therapeutic agent delivery in biomedical field.
Targeted delivery is an important area of biomedical research, which can reduce side effects in clinical field. Various carriers, such as organic, inorganic particles, liposome, polymer, etc., have been utilized in targeted delivery. However, these vehicles have several difficulties such as the complexity of synthesis, heterogeneous size and shape and lower biocompatibility. Protein nanoparticles could be an attractive candidate as delivery vehicles. Protein nanoparticles have well-defined structure with high symmetry, uniform size and shape. These particles have also biodegradability, greater stability during in vivo circulation and being easy to prepare the particles. And protein nanoparticles can attach drugs, fluorescent dye, enzymes, radioactive isotopes, antigens, or antibodies at desired site depending on their purpose.
In this study, we used Aquifex aeolicus Lumazine synthase (AaLS) as a targeted delivery vehicle. Antibody binding domain (ABD), which was known to selectively bind to Fc part of the antibody, was genetically encoded to AaLS (ABD-AaLS). We have designed a modular delivery platform that can deliver drugs to a variety of cancer cells by binding various antibodies to ABD. This platform can deliver drug to variety of target cancer cells in in vitro.
Recently we have developed a targeted delivery platform using P22 virus-like particle (P22 VLP) that is relatively large-sized protein cage nanoparticles. We covalently attached affibody to exterior surface of P22 VLP using bacterial superglue system. These platforms successfully delivered anticancer drug, doxorubicin, to tumor site and showed tumor specific killing effect.
In addition, we developed the cloaking drug delivery system using mesoporous silica nanoparticles (MSNs). We constructed GST fused affibody molecules and bound these fusion proteins on MSNs as capping materials. This pre-coated nanoparticles blocked nonspecific binding of serum proteins, avoiding immune response, while maintaining targeting ability in vivo.
Our studies demonstrated that protein nanoparticles are promising platforms for diagnostic and/or therapeutic agent delivery in biomedical field.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.